Tianjin Hospital

Running trials

• Recruiting

  Active Surveillance Versus Adjuvant Intravesical Chemotherapy in Liquid Biopsy-Defined Low-Shedding Intermediate-Risk NMIBC

  NCT07749924· Source

• Recruiting

  Is Prolonged Systemic Immunotherapy Necessary After Achieving Tumor-free Status in Patients With Extensive Transurethrally Unresectable Very-high-risk NMIBC?

  NCT07625527· Phase 2· Source

• Recruiting

  Urinary Tumor DNA-Guided Systemic Immunotherapy for Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer

  NCT07475403· Phase 2· Source

• Recruiting

  Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight

  NCT07353931· Phase 3· Source

• Active, not recruiting

  Guiding Value of Urinary Tumor DNA Testing in Cystoscopy for High-Risk/Very High-Risk Non-Muscle-Invasive Bladder Cancer

  NCT07180212· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Bladder cancer3 recruiting
• Obesity1 recruiting
• Osteoarthritis1 recruiting

Researchers

No researcher is linked here yet.